GSK and University of Dundee begin collaboration to develop therapies for rare genetic skin disorders


24th June 2011

GlaxoSmithKline and the University of Dundee have entered into an agreement to combine the pharmaceutical company's expertise in discovering and developing new medicines with the researcher's expertise in rare and debilitating skin disorders under GSK's Discovery Partnerships with Academia initiative.

The aim of the collaboration with Irwin McLean, Professor of Human Genetics and Head of Molecular Medicine at Dundee, is to develop new treatments for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare condition where the skin and other surfaces of the body can develop deep blisters with even mild pressure.

Read more.

Back to news